ALGRX 4975 in the Treatment of Tennis Elbow
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Randomized, Double-Blind, Placebo-Controlled, Phase II, Exploratory Evaluation of ALGRX 4975 in Subjects With Acute Lateral Epicondylitis|
- Pain induced by resisted wrist dorsiflexion 4 weeks after treatment
- Pain induced by resisted wrist dorsiflexion (other than 4 weeks)
- Grip strength
- Pain experienced during the grip strength test
- Pain in elbow over previous 24 hours
- Effect on work
- Tenderness elicited by investigator or designee
- Subjects' global impression of change
- Secondary outcomes are evaluated at 1, 2, 4, 8 and 12 weeks.
|Study Start Date:||November 2004|
|Estimated Study Completion Date:||November 2005|
Lateral epicondylitis (tennis elbow) is a painful condition that affects 4 to 7 adults per 1000 annually and tends to involve the subject’s dominant side. It typically results from repetitive arm movement with over use of muscles leading to small tears in the tendons attaching muscles of the forearm to the epicondyles that may progress to tendonitis. Pain on or around the lateral epicondyle may radiate down the subject’s arm. Gripping or extending the wrist often intensifies the pain.
More than 40 possible treatments have been proposed, reflecting a lack of consensus about optimal management. Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat tennis elbow, but there are no trials to date that have compared them with other painkillers and one study found no clinically important benefit over placebo. Use of corticosteroid injections provides mixed results in relief of pain and at times insufficient evidence to support their use. Although complications associated with steroid injection are relatively uncommon, when a complication does occur, it can result in severe and disabling consequences for the subject. A small proportion of subjects fail to respond to only one injection of corticosteroid and some subjects who initially improved at four weeks had worse symptoms by six months.
This study has been designed to evaluate the safety and efficacy of a single soft tissue injection of ALGRX 4975 at a dose of 100 µg in comparison to placebo in subjects with acute LE.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00130949
|Kosice, Slovakia, 040 11|
|Principal Investigator:||Gabriel Vasko, MD PhD||Ortopedicko-Traumatologicka Klinika, Kosice, Slovak Republic|